The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Open accessAbstract
Recent experiments have demonstrated that the Polycomb group (PcG) gene EZH2 is highly expressed in metastatic prostate cancer and in lymphomas. EZH2 is a component of the PRC2 histone methyltransferase complex, which also contains EED and SUZ12 and is required for the silencing of HOX gene expression during embryonic development. Here we demonstrate that both EZH2 and EED are essential for the proliferation of both transformed and non-transformed human cells. In addition, the pRB-E2F pathway tightly regulates their expression and, consistent with this, we find that EZH2 is highly expressed in a large set of human tumors. These results raise the question whether EZH2 is a marker of proliferation or if it is actually contributing to tumor formation. Significantly, we propose that EZH2 is a bona fide oncogene, since we find that ectopic expression of EZH2 is capable of providing a proliferative advantage to primary cells and, in addition, its gene locus is specifically amplified in several primary tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Barlund, M. T., Schraml, P., Leighton, S. B., Torhorst, J. K. H., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,101
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
The regulation of E2F by pRB-family proteins.
Dyson, N. (1998) · Genes & Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317
Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002) · Genes & Development · doi:10.1101/gad.1035902 · Cited by 1,596
Jacobs, J. J. L., Kieboom, K., Marino, S., DePinho, R. A., & van Lohuizen, M. (1999) · Nature · doi:10.1038/16476 · Cited by 1,580
Histone Methyltransferase Activity of a Drosophila Polycomb Group Repressor Complex
Müller, J., Hart, C. M., Francis, N. J., Vargas, M. L., Sengupta, A. K., Wild, B., Miller, E., O’Connor, M. B., Kingston, R. E., & Simon, J. A. (2002) · Cell · doi:10.1016/s0092-8674(02)00976-5 · Cited by 1,553
Czermin, B., Melfi, R., McCabe, D., Seitz, V., Imhof, A., & Pirrotta, V. (2002) · Cell · doi:10.1016/s0092-8674(02)00975-3 · Cited by 1,536
Pollack, J. R., Sørlie, T., Perou, C. M., Rees, C. A., Jeffrey, S. S., Lønning, P. E., Tibshirani, R. J., Botstein, D., Børresen‐Dale, A., & Brown, P. O. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162471999 · Cited by 1,167
Cited by
Sorted by citations
Items 901–999 of 999
Loss of H3K27me3 in WHO grade 3 meningioma
Maier, A. D., Brøchner, C. B., Mirian, C., Haslund-Vinding, J. L., Bartek, J. J., Ekström, T. J., Poulsen, F. R., Scheie, D., & Mathiesen, T. I. (2022) · Brain Tumor Pathology · doi:10.1007/s10014-022-00436-3 · Cited by 9
Native gel analysis of macromolecular protein complexes in cultured mammalian cells
Munawar, N., Olivero, G., Jerman, E., Doyle, B., Streubel, G., Wynne, K. J., Bracken, A. P., & Cagney, G. (2015) · PROTEOMICS · doi:10.1002/pmic.201500045 · Cited by 10
Self-citationPriming the renal progenitor cell
Iglesias, D. M., Akpa, M. M., & Goodyer, P. (2014) · Pediatric Nephrology · doi:10.1007/s00467-013-2685-3 · Cited by 9
Zhan, X., Yang, J., Mao, Z., & Yu, W. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.070 · Cited by 9
Rottlerin inhibits cell growth and invasion via down-regulation of EZH2 in prostate cancer
Zheng, N., Wang, L., Hou, Y., Zhou, X., He, Y., & Wang, Z. P. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1542897 · Cited by 9
Polycomb group proteins – epigenetic repressors with emerging roles in melanocytes and melanoma
Huang, J. M., & Hornyak, T. J. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12341 · Cited by 9
Endogenous double-stranded RNA: Bridging immune activation and cancer therapeutics
Liu, X., Che, L., & Weng, H. (2025) · Cell investigation. · doi:10.1016/j.clnves.2025.100018 · Cited by 10
EZH2 Inhibition Sensitizes IDH1R132H-Mutant Gliomas to Histone Deacetylase Inhibitor
Sprinzen, L., Garcia, F., Mela, A., Lei, L., Upadhyayula, P. S., Mahajan, A., Humala, N., Manier, L., Caprioli, R. M., Quiñones‐Hinojosa, A., et al. (2024) · Cells · doi:10.3390/cells13030219 · Cited by 8
Novel insights into RB1 in prostate cancer lineage plasticity and drug resistance
Ma, M., Zhu, Y., Xiao, C., Li, R., Cao, X., Kang, R., Wang, X., & Li, E. (2024) · Tumori Journal · doi:10.1177/03008916231225576 · Cited by 10
A new transgenic mouse model for conditional overexpression of the Polycomb Group protein EZH2
Koppens, M. A. J., Tanger, E., Nacerddine, K., Westerman, B. A., Song, J., & van Lohuizen, M. (2016) · Transgenic Research · doi:10.1007/s11248-016-9993-x · Cited by 8
Small Molecular Immune Modulators as Anticancer Agents
Han, Y., Zhu, L., Wu, W., Zhang, H., Hu, W., Dai, L., & Yang, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_22 · Cited by 8
Richard, S. A., & Kuugbee, E. D. (2021) · Analytical Cellular Pathology · doi:10.1155/2021/4907167 · Cited by 8
Kanayama, M., & Luo, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312742 · Cited by 8
The role of EZH2 as a potential therapeutic target in retinoblastoma
Zhao, Y., Cheng, Y., & Qu, Y. (2023) · Experimental Eye Research · doi:10.1016/j.exer.2023.109389 · Cited by 8
Cofré, J., Saalfeld, K., & Abdelhay, E. (2019) · The Scientific World JOURNAL · doi:10.1155/2019/4714781 · Cited by 10
Cai, Q., Wen, K., Ma, M., Chen, W., Mo, D., He, Z., Chen, Y., & Cong, P. (2020) · Biology of Reproduction · doi:10.1093/biolre/ioaa214 · Cited by 8
HMGA1 induces EZH2 overexpression in human B-cell lymphomas.
Martino, M. D., Nicolau‐Neto, P., Pinto, L. F. R., Traverse‐Glehen, A., Bachy, E., Gigantino, V., Cecio, R. D., Bertoni, F., Chieffi, P., Fusco, A., et al. (2021) · PubMed Central · Cited by 8
Epigenetic Regulation of Cancer Stem Cell Gene Expression
Bapat, S. A. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-4525-4_18 · Cited by 8
Chromosomal rearrangements in PLAG1 of myoepithelial salivary gland tumours.
Friedrich, R. E., Dilcher, J., Jaehne, M., & Löning, T. (2012) · PubMed · Cited by 8
The TGFβ→TAK1→LATS→YAP1 Pathway Regulates the Spatiotemporal Dynamics of YAP1
Kim, M., Han, S.-H., Park, T.-G., Song, S.-H., Lee, J.-Y., Lee, Y., Yoo, S.-Y., Chi, X., Kim, E., Jang, J., et al. (2023) · Molecules and Cells · doi:10.14348/molcells.2023.0088 · Cited by 6
Kundu, S., Rohokale, R., Lin, C., Chen, S., Biswas, S., & Guo, Z. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100570 · Cited by 7
Li, Y., Su, S., Luo, Y., Wei, C., He, J., Song, L., Han, K., Wang, J., Gan, X., & Wang, D. (2025) · Oncology Reports · doi:10.3892/or.2025.8942 · Cited by 9
Jacobi, J. J., Wadosky, K. M., Jaiswal, N., Zhang, X., Wang, Y., Singh, P. K., Wang, J., Gomez, E. C., Wang, J., Xu, B., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-2747 · Cited by 10
Swalm, B. M., Hallenbeck, K. K., Majer, C. R., Jin, L., Scott, M. P., Moyer, M. P., Copeland, R. A., & Wigle, T. J. (2013) · Biochemical Journal · doi:10.1042/bj20130439 · Cited by 7
Ozgun, G., Yaraş, T., Akman, B., Özden-Yılmaz, G., Landman, N., Karakülah, G., van Lohuizen, M., Şentürk, Ş., & Erkek, S. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00725-3 · Cited by 7
Kang, M. (2010) · Cell Cycle · doi:10.4161/cc.9.14.12322 · Cited by 7
Polycomb group proteins in hematopoietic stem cell aging and malignancies
Klauke, K., & de Haan, G. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0857-0 · Cited by 8
Epigenetic Targets in Human Neoplasms
Fandy, T. E., & Gore, S. D. (2010) · Epigenomics · doi:10.2217/epi.10.1 · Cited by 7
The E2F6 Transcription Factor is Associated with the Mammalian SUZ12-Containing Polycomb Complex
Shirahama, Y., & Yamamoto, K. (2020) · The Kurume Medical Journal · doi:10.2739/kurumemedj.ms674006 · Cited by 12
Epigenetic markers in human gliomas: prospects for therapeutic intervention
Hesson, L. B., Krex, D., & Latif, F. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.10.1475 · Cited by 7
Suresh, K., Kliot, T., Piunti, A., & Kliot, M. (2016) · Surgical Neurology International · doi:10.4103/2152-7806.194058 · Cited by 7
Wang, X., & Xu, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00159 · Cited by 7
Ezh1 regulates expression of Cpg15/Neuritin in mouse cortical neurons
Utsunomiya, S., Kishi, Y., Tsuboi, M., Kawaguchi, D., Gotoh, Y., Abe, M., Sakimura, K., Maeda, K., & Takemoto, H. (2021) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2021.01017 · Cited by 7
New molecular tumor markers for endometrial cancer.
Numa, F., Umayahara, K., Suehiro, Y., Suminami, Y., Oga, A., Sasaki, K., & Kato, H. (2001) · PubMed · Cited by 7
Yalçınkaya, U., Uğraş, N., Özgün, G., Ocakoğlu, G., Deligönül, A., Çetintaş, S., & Bilgen, M. S. (2017) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2017.1938 · Cited by 6
Ball, S., Aguirre, L. E. E., Jain, A. G., Ali, N. E. A., Tinsley, S., Chan, O., Kuykendall, A. T., Sweet, K. L., Lancet, J. E., Sallman, D. A., et al. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106999 · Cited by 6
Su, Z., Zhang, M., Luo, H., Zhong, J., Tan, J., Xu, Y., Pan, X., Zeng, H., Nie, L., Xu, M., et al. (2022) · Cancer Science · doi:10.1111/cas.15694 · Cited by 6
Hatada, I. (2009) · Springer eBooks · doi:10.1007/978-90-481-2675-0_4 · Cited by 6
Targeting Cancer at the Intersection of Signaling and Epigenetics
Guerra, S. L., & Cichowski, K. M. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050400 · Cited by 7
Carcinogenic roles and therapeutic effects of EZH2 in gynecological cancers
Wan, Z., Jiang, H., Li, L., Zhu, S., Hou, J., & Yu, Y. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115379 · Cited by 6
SETD2 and EZH2: Two epigenetic drivers of prostate cancer
Wang, J., Xiang, L., Zhang, H., & Zhang, X. (2025) · Journal of Cancer · doi:10.7150/jca.115715 · Cited by 6
Wang, Y., Ma, C., Liu, X., Cheng, J., Zhu, D., Liu, P., Qi, P., Li, X., Gu, J., & Wang, Q. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118590 · Cited by 7
Genetic Impairments of PRC2 Activity in Oncology: Problems and Prospects
Chetverina, D., Ломаев, Д. В., Georgiev, P. G., & Erokhin, M. (2021) · Russian Journal of Genetics · doi:10.1134/s1022795421030042 · Cited by 5
EZH2 Expression in Retinoblastoma: A Potential Therapeutic Target
Lin, Z., Tang, L., Chen, S., Zhang, W., Lin, J., Gao, H., & Zhang, P. (2023) · Ophthalmic Research · doi:10.1159/000531530 · Cited by 5
Chai, J. N., Choudhuri, J., Gong, J. Z., Wang, Y., & Tian, X. (2024) · Cancers · doi:10.3390/cancers16030646 · Cited by 5
Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer
Walsh, L., Gallagher, W. M., O’Connor, D. P., & Chonghaile, T. N. (2016) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1156534 · Cited by 5
Kelly, A. D., & Issa, J. J. (2016) · Energy balance and cancer · doi:10.1007/978-3-319-41610-6_1 · Cited by 5
PAR-Induced Harnessing of EZH2 to β-Catenin: Implications for Colorectal Cancer
Sedley, S., Nag, J. K., Rudina, T., & Bar‐Shavit, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158758 · Cited by 5
Li, J., Tan, R., Wu, J., Guo, W., Wang, Y., You, G., Zhang, Y., Yu, Z., Geng, Y., Zan, J., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1099148 · Cited by 5
Jonchère, B., Vétillard, A., Toutain, B., Guette, C., & Coqueret, O. (2016) · Bulletin du Cancer · doi:10.1016/j.bulcan.2015.10.014 · Cited by 5
Zhang, H. M., Chen, S. Q., & Yao, S. (2016) · Genetics and Molecular Research · doi:10.4238/gmr.15027408 · Cited by 5
QUANTITATIVE MULTIGENE EXPRESSION PROFILING OF PRIMARY PROSTATE CANCER
Meye, A., Schmidt, U., Fuessel, S., Koch, R., Baretton, G. B., Froehner, M., & Wirth, M. P. (2006) · European Urology Supplements · doi:10.1016/s1569-9056(06)60117-6 · Cited by 5
The dysregulated YY1-EZH2-RKIP axis in cancer cells and immune evasion
Festekdjian, T., & Bonavida, B. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189424 · Cited by 4
Noncanonical association of EZH2 with E2F1 promotes tumor proliferation through chromatin remodeling
Yoo, M., Lee, H., Park, H., Kang, B., Kim, H., Kim, T.-K., & Roh, T. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01603-0 · Cited by 4
Novel role of lncRNAs regulatory network in papillary thyroid cancer
Su, Y., Mei, L., Jiang, T., Jiang, T., Sun, T., Wu, Y., Wang, Z., & Ji, Y. (2024) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2024.101674 · Cited by 4
Bai, Y.-K., Sun, J., Wang, Y., Zheng, N., Xu, Q.-L., & Wang, Y. (2023) · Oncology Letters · doi:10.3892/ol.2023.13902 · Cited by 4
Regulation of EZH2 Expression by INPP4B in Normal Prostate and Primary Prostate Cancer
Zhang, M., Ceyhan, Y., Mei, S., Hirz, T., Sykes, D. B., & Agoulnik, I. U. (2023) · Cancers · doi:10.3390/cancers15225418 · Cited by 4
Epigenetic Cooperativity as a Therapeutic Vulnerability in Cancer
Kazansky, Y., & Kentsis, A. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-2924 · Cited by 4
Understanding the molecular regulators of neuroendocrine prostate cancer
Bhattacharya, S., Stillahn, A., Smith, K., Muders, M. H., Datta, K., & Dutta, S. (2024) · Advances in cancer research · doi:10.1016/bs.acr.2024.04.006 · Cited by 4
Solanki, R., Malik, M. Z., Alankar, B., Ahmad, F. J., Dohare, R., Chauhan, R., Kesharwani, P., & Kaur, H. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155431 · Cited by 4
E2F Transcription Factors in Cancer, More than the Cell Cycle
Broeker, C. D., & Andrechek, E. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00102-x · Cited by 5
Akman, B., Bursalı, A., Gürses, M., Süner, A., Karakülah, G., Mungan, U., Yörükoğlu, K., & Erkek, S. (2024) · Cancer Science · doi:10.1111/cas.16275 · Cited by 4
Breast Cancer Heterogeneity: A focus on Epigenetics and In Vitro 3D Model Systems.
Suresh, P. K. (2018) · Europe PMC (PubMed Central) · doi:10.22074/cellj.2018.5442 · Cited by 4
Colecchia, F., Kottwitz, D., Wagner, M., Pfenninger, C. V., Thiel, G., Tamm, I., Peterson, C., & Nuber, U. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp311 · Cited by 4
MK3 Modulation Affects BMI1-Dependent and Independent Cell Cycle Check-Points
Prickaerts, P., Niessen, H. E. C., Dahlmans, V. E. H., Spaapen, F., Salvaing, J., Vanhove, J., Geijselaers, C., Bartels, S. J. J., Partouns, I., Neumann, D., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118840 · Cited by 4
A missense variant in EZH2 is associated with colorectal cancer risk in a Chinese population
Li, H., Chang, C., Shang, Y., Qiang, L., Zhang, B., Bu, B., Ren, G., Song, L., Shang, M., & Yu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.21888 · Cited by 4
Meenakshi, S., Maharana, K. C., Nama, L., Vadla, U. K., Dhingra, S., Ravichandiran, V., Murti, K., & Kumar, N. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230809110444 · Cited by 3
Li, J., Hua, H., Liu, X., Zhou, Z., Yuan, J., & Wang, F. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115154 · Cited by 3
Brown, R. E., Fuchter, M., Curry, E. W., Green, I. A., Kandil, S., Cherblanc, F., Payne, L., Chapman‐Rothe, N., Shamsaei, E., Srimongkolpithak, N., et al. (2014) · European Journal of Cancer · doi:10.1016/s0959-8049(14)70680-x · Cited by 3
Perspectives of FRET Imaging to Study Epigenetics and Mechanobiology in the Nucleus
Qin, P., Cheng, B., Lu, S., Chien, S., & Wang, Y. (2016) · Springer eBooks · doi:10.1007/978-1-4939-5617-3_7 · Cited by 3
Polycomb Repressive Complex 2 Structure and Function
Holoch, D., & Margueron, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809737-3.00009-x · Cited by 3
Qin, W., Wang, X., Zhao, H., & Lu, H. J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00293 · Cited by 3
Vaz, M., & Fahrenkrog, B. (2021) · Cells · doi:10.3390/cells10112851 · Cited by 3
Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance
Rytlewski, J. D., Brockman, Q. R., Dodd, R. D., Milhem, M. M., & Monga, V. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.88 · Cited by 3
Protein Lysine Methyltransferases Inhibitors
Li, Y., Ding, L., Ren, S., Zhang, W., & Rao, G. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220829151257 · Cited by 3
Chen, M., Yao, X., Ping, J., Shen, H., Wei, Y., & Wang, W. (2023) · International Journal of Surgical Pathology · doi:10.1177/10668969221146204 · Cited by 3
Lin, Y., Su, H., Zou, B., & Huang, M. (2023) · Current Eye Research · doi:10.1080/02713683.2023.2257401 · Cited by 3
Kim, D. H., Siddiqui, S., Jain, P., Wang, M. L., Thakral, B., Li, S., Miranda, R. N., Vega, F., Medeiros, L. J., & Ok, C. Y. (2024) · Human Pathology · doi:10.1016/j.humpath.2024.03.002 · Cited by 3
Epigenetic Factors: Key Regulators Targeted in Cancers
Yeo-Teh, N. S. L., Ito, Y., & Jha, S. (2018) · InTech eBooks · doi:10.5772/intechopen.73040 · Cited by 3
Cytosine Methyltransferases as Tumor Markers
Pavlopoulou, A., & Κοσσίδα, Σ. (2010) · Current Genomics · doi:10.2174/138920210793360916 · Cited by 3
Histone Methyltransferases: Opportunities in Cancer Drug Discovery
Chesworth, R., Wigle, T. J., Kuntz, K. W., Smith, J. J., & Richon, V. M. (2013) · Springer eBooks · doi:10.1007/978-3-642-38404-2_9 · Cited by 3
Misregulation of Histone Methylation Regulators in Cancer
Ooi, W. F., Yao, X., Tan, P. B. O., & Teh, B. T. (2017) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-59786-7_8 · Cited by 3
Hematopoietic Stem Cell Biology
Rossmann, M. P., Orkin, S. H., & Chute, J. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00009-3 · Cited by 3
Epigenetics of Prostate Cancer and Novel Chemopreventive and Therapeutic Approaches
Bhagirath, D., Yang, T. L., Dahiya, R., Majid, S., & Saini, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812494-9.00014-7 · Cited by 3
Francipane, M. G., & Lagasse, E. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7876-8_14 · Cited by 3
The PRC2.1 subcomplex opposes G1 progression through regulation of CCND1 and CCND2Preprint
Longhurst, A. D., Wang, K., Suresh, H. G., Ketavarapu, M., Ward, H. N., Jones, I. R., Narayan, V., Hundley, F. V., Hassan, A. Z., Boone, C. M., et al. (2024) · eLife · doi:10.7554/elife.97577 · Cited by 5
Li, P., Fujisawa, T., Narita, H., Uneme, Y., Seki, M., Hu, M., Narumi, R., Namekawa, S. H., Khan, S. S., Davie, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.24.625111 · Cited by 3
Chromatin Regulatory Targets for Anticancer Therapeutics
Barta, P. A., Carter, T. R., & Erb, M. A. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00231 · Cited by 2
Epigenetic Regulators as Therapeutic Targets in Pancreatic Ductal Adenocarcinoma
Kubiak, K., & Inkielewicz‐Stępniak, I. (2026) · Cancers · doi:10.3390/cancers18061001 · Cited by 2
Epigenetic Regulation of Pluripotency by Polycomb Group Proteins
Breiling, A. (2014) · Epigenetics and human health · doi:10.1007/978-3-642-31974-7_6 · Cited by 2
Activating Mutations of the EZH2 Histone Methyltransferase in Cancer
Kruger, R. G., Graves, A. P., & McCabe, M. T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809737-3.00011-8 · Cited by 2
(2005) · Springer eBooks · doi:10.1007/3-540-29623-9_8981 · Cited by 2
The Human Epigenome—Implications for the Understanding of Human Disease
Esteller, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802761-5.00008-0 · Cited by 2
Polycomb Repressive Complex 2 in Oncology
Guo, Y., Yu, Y., & Wang, G. G. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-45654-1_9 · Cited by 2
Wang, H., Wang, L., Zhang, S., Liu, Q., & Gao, F. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03362-w · Cited by 2
EZH2 as a therapeutic target in solid tumors
(2015) · Cancer Cell & Microenvironment · doi:10.14800/ccm.1024 · Cited by 2
Large at birth lifespan dearth?
Lin, S.-J. (2011) · Cell Cycle · doi:10.4161/cc.10.4.14850 · Cited by 2
Karmaker, A., Yoon, K., Doderer, M. S., Kruzelock, R. P., & Kwek, S. S. (2007) · Berichte aus der medizinischen Informatik und Bioinformatik/Journal of integrative bioinformatics · doi:10.1515/jib-2007-59 · Cited by 2
Polycomb Group Protein Homeostasis in Stem Cell Identity – A Hypothetical Appraisal
Rajasekhar, V. K. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-227-8_24 · Cited by 2
Metadata
- Authors
- Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K.
- Affiliations
- European Institute of Oncology (IT)
- IFOM (IT)
- Corresponding author
- Helin, Kristian
- Venue
- The EMBO Journal
- Published
- 2003-10-15
- Volume
- 22
- Issue
- 20
- Pages
- 5323-5335
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- PMC
- PMC213796
- OpenAlex
- W2171439874
- Cited by
- 1,196
- References
- 43
- Citations by year
- 2026: 16 · 2025: 33 · 2024: 39 · 2023: 52 · 2022: 35 · 2021: 64 · 2020: 66 · 2019: 56 · 2018: 53 · 2017: 65 · 2016: 74 · 2015: 63 · 2014: 65 · 2013: 61 · 2012: 58
- FWCI
- 11.03
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-02-12)
- Open access
- green
- europepmc.org
- Locations
- The EMBO Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- European Commission
- Associazione Italiana per la Ricerca sul Cancro
- Fondazione Italiana per la Ricerca sul Cancro
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- EZH2, Polycomb group genes, polycomb repressive complex 2, EED, oncogenes, cell proliferation, gene amplification, prostate cancer, lymphoma, histone methyltransferase, tumor formation
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, Animals, Base Sequence, Cell Division, Cell Line, DNA-Binding Proteins, Gene Amplification, Genetic Markers, Humans, Kinetics, Lymphoma, Male, Oncogenes, Promoter Regions, Genetic, Prostatic Neoplasms, Proteins, Recombinant Proteins, Transcription Factors, Transfection, Transcriptional Activation, Retinoblastoma Protein, DNA Primers, Cell Cycle Proteins, E2F Transcription Factors, Rats, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
